OUTPATIENT TREATMENT--TARGETED VS MAINTENANCE MEDICATION

门诊治疗——靶向药物与维持药物

基本信息

  • 批准号:
    2244457
  • 负责人:
  • 金额:
    $ 36.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1987
  • 资助国家:
    美国
  • 起止时间:
    1987-09-01 至 1997-08-31
  • 项目状态:
    已结题

项目摘要

During the first five years of this project, we compared the efficacy of a targeted, early intervention strategy using neuroleptic medication with a strategy using early intervention (increased dosage) that supplemented ongoing maintenance neuroleptic therapy. Our experience to date is useful for the work proposed in the current application in several ways. First, we have developed a rapid, effective pharmacologic intervention at relapse for patients assigned to either drug-free or experimental drug status. Since targeted, early intervention treatment efforts are feasible and effective, the consequences of ineffective experimental or placebo treatment need not be severe deterioration in clinical state. Second, our experience with the early intervention, targeted neuroleptic strategy suggests the likelihood that highly sensitive detection of a prodromal syndrome includes symptoms that are false-positive with respect to relapse and often includes psychopathology likely to be susceptible to anxiolytic drug treatment. Third, we now have a trained and experienced clinical staff with established competence in dealing with chronically and severely mentally ill patients within the protocol demands of controlled clinical studies. Fourth, we have gained the logistical experience necessary for conducting outpatient clinical trials. As originally described, the specific aims of the project were to determine the relative effectiveness of two pharmacotherapeutic approaches to the care of schizophrenic outpatients, one involving the targeted use of neuroleptic drugs for symptom exacerbation and the other involving the use of these same drugs for maintenance purposes. At the outset, the feasibility and ethics of the noncontinuous targeted approach were heatedly debated; however, the potential advantages of this alternative strategy for the actively noncompliant patient were compelling, and there was a growing appreciation that placebo controlled continuous drug trials had not addressed the central hypothesis of this project. The possibility that this approach would be a feasible alternative for a substantial proportion of schizophrenic patients was sufficiently attractive to merit empirical evaluation in a random assignment, comparative treatment study. The immediate goal was to ascertain if a substantial reduction in the use of neuroleptic drugs could be achieved without adversely affecting course and outcome status as reflected in symptomatic clinical decompensation and the need for hospital care.
在这个项目的前五年,我们比较了 有针对性的早期干预策略的有效性, 抗精神病药物与早期干预策略 (增加剂量)补充持续维持 神经抑制剂治疗 我们迄今为止的经验对 本申请中提出的工作以几种方式进行。 第一、 我们开发了一种快速有效的药物干预 对于分配至无药物或 实验药物状态。 有针对性的早期干预 治疗措施是可行和有效的, 无效的实验或安慰剂治疗不一定严重 临床状态恶化。 第二,我们的经验 早期干预、有针对性的神经安定药策略表明, 对前驱综合征的高灵敏度检测 包括复发方面的假阳性症状 通常包括精神病理学, 抗焦虑药物治疗 第三,我们现在有一个训练有素的, 经验丰富的临床工作人员,在处理 患有慢性和严重精神疾病的患者, 对照临床研究的方案要求。 四是 获得了必要的后勤经验, 门诊临床试验。 如最初所述,该项目的具体目标是 确定两种药物的相对有效性 精神分裂症门诊病人的护理方法,其中包括 针对症状加重的抗精神病药物的靶向使用 另一种是使用同样的药物 维护目的。 从一开始, 非连续性定向治疗方法引起了激烈的争论; 然而,这种替代战略的潜在优势, 主动不依从患者是令人信服的, 越来越多的人认识到安慰剂控制了连续用药, 试验没有解决这个项目的中心假设。 这一办法成为可行替代办法的可能性 很大一部分精神分裂症患者 有足够的吸引力,值得在一个随机的经验评估 分配,比较治疗研究。 目前的目标是确定是否大幅度减少 使用精神抑制药物可以实现, 影响病程和结局状态, 临床失代偿和需要住院治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William T. Carpenter其他文献

Risperidone versus typical antipsychotic medication for schizophrenia
  • DOI:
    10.1007/s11920-000-0017-3
  • 发表时间:
    2000-09-01
  • 期刊:
  • 影响因子:
    6.700
  • 作者:
    William T. Carpenter
  • 通讯作者:
    William T. Carpenter
The diagnosis and understanding of schizophrenia. Part II. Expanded perspectives for describing and comparing schizophrenic patients.
精神分裂症的诊断和认识。
  • DOI:
    10.1093/schbul/1.11.50
  • 发表时间:
    1974
  • 期刊:
  • 影响因子:
    6.6
  • 作者:
    J. Bartko;John S. Strauss;William T. Carpenter
  • 通讯作者:
    William T. Carpenter
SHOULD WE CONTINUE TO DO PLACEBO-CONTROLLED MEDICATION TRIALS IN SCHIZOPHRENIA? AN ETHICO-CLINICAL DEBATE
  • DOI:
    10.1016/s0920-9964(14)70042-8
  • 发表时间:
    2014-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Anthony S. David;William T. Carpenter
  • 通讯作者:
    William T. Carpenter
Olanzapine for schizophrenia
  • DOI:
    10.1007/s11920-000-0018-2
  • 发表时间:
    2000-09-01
  • 期刊:
  • 影响因子:
    6.700
  • 作者:
    William T. Carpenter
  • 通讯作者:
    William T. Carpenter
Advances in schizophrenia
精神分裂症的进展
  • DOI:
    10.1038/89040
  • 发表时间:
    2001-06-01
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Gunvant K. Thaker;William T. Carpenter
  • 通讯作者:
    William T. Carpenter

William T. Carpenter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William T. Carpenter', 18)}}的其他基金

A 3T Scanner for Establishing UM MPRC Neuroimaging Research Facility
用于建立 UM MPRC 神经影像研究设施的 3T 扫描仪
  • 批准号:
    7842843
  • 财政年份:
    2010
  • 资助金额:
    $ 36.08万
  • 项目类别:
Center for Intervention Development and Applied Research
干预开发和应用研究中心
  • 批准号:
    7812750
  • 财政年份:
    2009
  • 资助金额:
    $ 36.08万
  • 项目类别:
Centers for Intervention Development and Applied Research (CIDAR)
干预发展和应用研究中心 (CIDAR)
  • 批准号:
    8327303
  • 财政年份:
    2008
  • 资助金额:
    $ 36.08万
  • 项目类别:
Centers for Intervention Development and Applied Research (CIDAR)
干预发展和应用研究中心 (CIDAR)
  • 批准号:
    8080317
  • 财政年份:
    2008
  • 资助金额:
    $ 36.08万
  • 项目类别:
Centers for Intervention Development and Applied Research (CIDAR)
干预发展和应用研究中心 (CIDAR)
  • 批准号:
    7690198
  • 财政年份:
    2008
  • 资助金额:
    $ 36.08万
  • 项目类别:
Centers for Intervention Development and Applied Research (CIDAR)
干预发展和应用研究中心 (CIDAR)
  • 批准号:
    7450397
  • 财政年份:
    2008
  • 资助金额:
    $ 36.08万
  • 项目类别:
Centers for Intervention Development and Applied Research (CIDAR)
干预发展和应用研究中心 (CIDAR)
  • 批准号:
    7892530
  • 财政年份:
    2008
  • 资助金额:
    $ 36.08万
  • 项目类别:
CORE--RESEARCH METHODS CORE
核心--研究方法核心
  • 批准号:
    7553490
  • 财政年份:
    2007
  • 资助金额:
    $ 36.08万
  • 项目类别:
Bios. and Data Man.
简介。
  • 批准号:
    7553493
  • 财政年份:
    2007
  • 资助金额:
    $ 36.08万
  • 项目类别:
CORE--PRINCIPAL RESEARCH CORE
核心--主要研究核心
  • 批准号:
    7553491
  • 财政年份:
    2007
  • 资助金额:
    $ 36.08万
  • 项目类别:

相似海外基金

CAREER: microRNA-mediated regulation of dosage sensitive genes involved in morphogenesis
职业:微小RNA介导的形态发生剂量敏感基因的调节
  • 批准号:
    2238425
  • 财政年份:
    2023
  • 资助金额:
    $ 36.08万
  • 项目类别:
    Continuing Grant
Evaluation of Transmission Low-frequency Raman Spectroscopy for Application to Quality Assurance of Continuous Manufactured Solid Dosage Forms
透射低频拉曼光谱在连续生产固体剂型质量保证中的应用评价
  • 批准号:
    23K06071
  • 财政年份:
    2023
  • 资助金额:
    $ 36.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Use of Additives in Oral Solid Dosage Forms to Inhibit Nitrosamine Formation
在口服固体剂型中使用添加剂抑制亚硝胺形成
  • 批准号:
    2896874
  • 财政年份:
    2023
  • 资助金额:
    $ 36.08万
  • 项目类别:
    Studentship
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
一项 2 期、随机、双盲、4 组、多中心研究,旨在证明处方药局部剂量制剂治疗光化性角化病的有效性和安全性
  • 批准号:
    10820810
  • 财政年份:
    2023
  • 资助金额:
    $ 36.08万
  • 项目类别:
Estimation of optimal dosage of opioid based on vascular stiffness value
基于血管硬度值估算阿片类药物最佳剂量
  • 批准号:
    23K15598
  • 财政年份:
    2023
  • 资助金额:
    $ 36.08万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mapping and prediction of quantitative transcription factor dosage effects to understand variation in craniofacial morphology and disease
定量转录因子剂量效应的绘图和预测,以了解颅面形态和疾病的变化
  • 批准号:
    10641572
  • 财政年份:
    2023
  • 资助金额:
    $ 36.08万
  • 项目类别:
Creation of trait diversity through gene dosage effects in allopolyploid wheat
通过异源多倍体小麦基因剂量效应创造性状多样性
  • 批准号:
    22KJ1943
  • 财政年份:
    2023
  • 资助金额:
    $ 36.08万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Optimizing dosage and CTA-Enabling Pre-clinical Gene Therapy Studies for Creatine Transporter Deficiency
优化剂量和支持 CTA 的肌酸转运蛋白缺乏症临床前基因治疗研究
  • 批准号:
    491901
  • 财政年份:
    2023
  • 资助金额:
    $ 36.08万
  • 项目类别:
    Operating Grants
SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72
社会是小企业关注 NCGC72 的剂型开发、生产和稳定性研究
  • 批准号:
    10953952
  • 财政年份:
    2023
  • 资助金额:
    $ 36.08万
  • 项目类别:
Polyploidization, gene dosage, and the evolution of hormonal phenotypes
多倍化、基因剂量和激素表型的进化
  • 批准号:
    2151409
  • 财政年份:
    2022
  • 资助金额:
    $ 36.08万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了